Loading clinical trials...
Loading clinical trials...
In this study we will assess the effect of Ketamine infusion on depressive symptoms and in particular its effect on Suicidal behavior, ideation and thoughts in patients with treatment- resistant MDD.
A Twice repetition of IV infusion of 0.5 mg/kg of ketamine produces an antidepressant response in individuals with treatment-resistant MDD The work aims to: 1. To assess the onset of action and degree of improvement and the duration of antidepressant effect of ketamine in a sample of patients with treatment -resistant major depressive disorder. 2. To find out whether the onset of Ketamine antidepressant effect is associated with an improvement of suicidality in those patients.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Assiut university
Asyut, Egypt
Start Date
September 1, 2020
Primary Completion Date
October 1, 2021
Completion Date
October 1, 2021
Last Updated
March 5, 2025
36
ACTUAL participants
Ketamine
DRUG
Lead Sponsor
Assiut University
NCT04480918
NCT04041479
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03320304